



## **Draig Therapeutics to Present at the European College of Neuropsychopharmacology (ECNP) Congress**

September 30, 2026 (Newton, MA, USA) - Draig Therapeutics, a clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric therapies, announced today that the company will present three posters at the European College of Neuropsychopharmacology (ECNP) Congress.

Poster session details:

**Poster Title:** DT-101, an  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor positive allosteric modulator, gave target-relevant magnetoencephalographic responses in healthy adults in first in human trial

**Session Title:** Poster Session 1

**Presentation Number:** PS01-1180

**Date:** Saturday, October 10th, 12:00 - 13:25

**Poster Title:** DT-101, an  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) positive allosteric modulator (PAM): Phase 1 safety, pharmacokinetic, and pharmacodynamic data in healthy volunteers

**Session Title:** Poster Session 4

**Presentation Number:** PS04-4195

**Date:** Tuesday, October 13th, 12:35 - 14:00, Poster Area

**Poster Title:** Pharmacological characterisation of a novel  $\alpha 2/3$  GABAA receptor selective positive allosteric modulator

**Session Title:** Poster Session 2

**Presentation Number:** PS02-2031

**Date:** Sunday, October 11th, 12:35 - 14:00, Poster Area

The 39<sup>th</sup> ECNP Congress will be held October 10-13, 2026, in Munich Germany.

### **About DT-101**

DT-101 is a Phase 2 AMPAR PAM and the lead program in Draig Therapeutics' pipeline of highly specific AMPAR & GABAAR modulators designed to enable safe, precise modulation of the major neurocircuits underlying neuropsychiatric disorders. Supported by clinically validated AMPAR biology, DT-101 is an investigational therapy for the potential treatment of major depressive disorder (MDD). It is a next-generation AMPAR PAM with potential best-in-class antidepressant efficacy and speed of onset. It has demonstrated a clean safety and tolerability profile with excellent CNS distribution and target engagement in Phase 1 development. It is currently being evaluated in TARIAN-1, a global, randomized, double-blind, placebo-controlled, Phase 2 study evaluating efficacy, safety, and tolerability of DT-101 in people with MDD. DT-101 is also currently being evaluated in AERON-1, a randomized, double-blind, placebo-controlled Phase 2 study to evaluate the effectiveness of DT-101 in an adjunct setting in patients with MDD in the U.S.

**About Draig Therapeutics**

Draig Therapeutics is a clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric therapies. Our pipeline of highly specific AMPAR & GABAAR modulators are designed to enable safe, precise modulation of the major neurocircuits underlying neuropsychiatric disorders. Our lead program, DT-101, is a Phase 2 AMPAR PAM with best-in-disease potential in major depressive disorder. Working in partnership with patients and their care partners, Draig is transforming the future of neuropsychiatry.

**Media Contact**

Megan Prock McGrath  
CTD Comms, LLC  
[megan@ctdcomms.com](mailto:megan@ctdcomms.com)